 |
 |
 |
 |
 |
||||
 |
||||||||
|
SPECIALTY PHARMA Acuity Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the treatment of ophthalmic diseases and leveraging its technology and intellectual property portfolio in the field of RNA interference. Acuity's technology comes out of the renowned University of Pennsylvania School of Medicine and the Scheie Eye Institute. Acuity's first products are for age-related macular degeneration ("AMD") and diabetic retinopathy ("DR"), two of the leading causes of adult vision loss in the developed world. The company's lead compound, currently in Phase I clinical trails, is a short interfering RNA therapeutic that stops the production of vascular endothelial growth factor, which is understood to be central to the disease pathways for AMD and DR. (Exited March 2007 via merger with Froptix Corp. New company to be named Opko.) Valera Pharmaceuticals, Inc. focuses on the development and the acquisition of novel therapeutics for the urology and endocrinology specialties and is advancing drug delivery with its innovative, state-of-the-art, Hydron Implant Technology. The company recently launched its first FDA-approved product, Vantas, a time-release implantable drug and delivery system, for treatment of metastatic prostate cancer. (Exited December 2006 via sale to Thermo Fisher Scientific, Inc.)
|
|
||||||
 |
||||||||
 |
||||||||
|
||||||||
